UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, DC 20549 Form 10-Q (Mark One )
? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934 For the Quarterly Period EndedJune 30, 2021 OR
? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF
1934 For the transition period from _____ to _____ Commission file number 000-19125Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter)Delaware 33-0336973
(State or other jurisdiction of (
incorporation or organization)
760-931-9200 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which Title of each class Trading symbol registered
Common Stock,
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ? No ?
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ? No ?
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer ? Accelerated Filer ?
Non-accelerated Filer ?
Emerging Growth Company ?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12(b)-2 of the Securities Exchange Act of 1934). Yes ? No ?
The number of shares of voting common stock outstanding as of
--------------------------------------------------------------------------------
IONIS PHARMACEUTICALS, INC. FORM 10-Q INDEX
PART I FINANCIAL INFORMATION
ITEM 1: Financial Statements:
Condensed Consolidated Balance Sheets as ofJune 30, 2021 andDecember 31, 2020 (unaudited) (as revised) 3 Condensed Consolidated Statements of Operations for the three and six months endedJune 30, 2021 and 2020 (unaudited) (as revised) 4 Condensed Consolidated Statements of Comprehensive Loss for the three and six months endedJune 30, 2021 and 2020 (unaudited) (as revised) 5 Condensed Consolidated Statements of Stockholders' Equity for the three and six months endedJune 30, 2021 and 2020 (unaudited) (as revised) 6 Condensed Consolidated Statements of Cash Flows for the six months endedJune 30, 2021 and 2020 (unaudited) (as revised) 7 Notes to Condensed Consolidated Financial Statements (unaudited) 8
ITEM 2: Management's Discussion and Analysis of Financial Condition and
Results of Operations: Overview 31 Results of Operations 34 Liquidity and Capital Resources 40 ITEM 3: Quantitative and Qualitative Disclosures about Market Risk 41 ITEM 4: Controls and Procedures 41 PART II OTHER INFORMATION 41 ITEM 1: Legal Proceedings 41 ITEM 1A: Risk Factors 42 ITEM 2: Unregistered Sales ofEquity Securities and Use of Proceeds 58 ITEM 3: Default uponSenior Securities 58 ITEM 4: Mine Safety Disclosures 58 ITEM 5: Other Information 58 ITEM 6: Exhibits 58 SIGNATURES 60 TRADEMARKS
"Ionis," the Ionis logo, and other trademarks or service marks of
--------------------------------------------------------------------------------
© Edgar Online, source